Clinical trials: Chemoradiotherapy
Malnutrition, Nasopharyngeal Carcinoma
Early Nutritional Intervention in NPC Patients Undergoing Concurrent Chemoradiotherapy
This single center, open-label, randomized controlled clinical trial was designed to investigate whether early nutritional intervention with oral nutrition supplements in patients with nasopharyngeal carcinoma undergoing…
- Trial name
- NCT04810936
- Testing
- oral nutritional supplements
- Where
- China
- Volunteers
- 272 people
- Sponsor
- Guangdong Provincial People's Hospital
Head and Neck Neoplasms, Carcinoma, Squamous
ctDNA and MRI Parameters in Head and Neck Cancer
Patients undergoing primary radiochhemotherapy for locally advanced head and neck squamous cell carcinomas are included in this study.
- Trial name
- NCT06215612
- Testing
- Blood draw, MRI
- Volunteers
- 50 people
- Sponsor
- Franziska Eckert
Esophageal Cancer, Squamous Cell Carcinoma
Low-Dose Nedaplatin (CDGP:Cis-Diammine-Glycolatoplatinum)/5-FU Combined With Radiation for Esophageal Cancer
The purpose of this study is to clarify efficacy and toxicity of daily low-dose Nedaplatin (CDGP) and continuous infusion of 5-FU combined with radiation in patients with esophageal squamous cell carcinoma.
- Trial name
- NCT00197444
- Testing
- CDGP/5-FU combined with radiation, Radiotherapy
- Where
- Japan
- Volunteers
- 33 people
- Sponsor
- Hamamatsu University
Squamous Cell Carcinoma of Oral Cavity
Adjuvant ChemoRadiotherapy Prior to Surgery in Stage IVa Oral Cancers
Oral cancer is the single largest cancer in males in India. 90-95% cases of oral cancer are Squamous cell carcinomas and many of them present at late stages (T3 and above).
- Trial name
- NCT03923998
- Testing
- Neoadjuvant chemotherapy, Neoadjuvant radiotherapy, Resection and reconstruction
- Where
- India
- Volunteers
- 8 people
- Sponsor
- Indrayani Hospital and Cancer Institute
Non-small Cell Lung Cancer
A Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in Patients With Unresectable Stage III Non-small Cell Lung Cancer
This is a phase I/II exploratory study to evaluate the efficacy and safety of anlotinib combined with concurrent chemoradiotherapy in the treatment of surgically unresectable stage III non-small cell lung cancer.
- Trial name
- NCT04958993
- Testing
- Anlotinib hydrochloride capsule Combined With Concurrent Chemoradiotherapy
- Where
- China
- Volunteers
- 7 people
- Sponsor
- Shandong Cancer Hospital and Institute
Rectal Cancer
Induction FOLFOX With or Without Aflibercept Followed by Chemoradiation in High Risk Locally Advanced Rectal Cancer
This trial compares induction treatment with FOLFOX with or without aflibercept in a high risk population selected by MRI, prior to receiving standard chemoradiation (capecitabine combined with 50.4 Gy in 28 days) and surgery, in…
- Trial name
- RIA (NCT02340949)
- Testing
- Aflibercept, 5-Fluoruracil, Oxaliplatin
- Volunteers
- 180 people
- Sponsor
- Grupo Espanol Multidisciplinario del Cancer Digestivo
Small Cell Lung Cancer Limited Stage
Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer
The purpose of this study is to evaluate the tolerability and toxicity of different dose of anlotinib combination with concurrent chemoradiotherapy in the treatment of limited-stage SCLC patients.
- Trial name
- NCT04882033
- Testing
- Concurrent chemoradiotherapy plus anlotinib
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer, Gastroesophageal Cancer
Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma
The goal of this clinical research study is to learn if a combination of the investigational drug oxaliplatin with 5-Fluorouracil (5-FU) (given at the same time as radiation therapy) is as effective as a combination of these two…
- Trial name
- NCT00525915
- Testing
- 5-Fluorouracil, Oxaliplatin, Radiation Therapy
- Where
- United States
- Volunteers
- 126 people
- Sponsor
- M.D. Anderson Cancer Center
Borderline Resectable Pancreatic Adenocarcinoma
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
The purpose of this study is to characterize the safety, preliminary efficacy, and immune biologic activity of CAN-2409 + prodrug (valacyclovir or acyclovir) in subjects with borderline resectable pancreatic cancer who are being…
- Trial name
- PaTK02 (NCT02446093)
- Testing
- Aglatimagene besadenovec, Chemoradiation, Stereotactic body radiation therapy
- Where
- 3 sites in United States, Mexico
- Volunteers
- 54 people
- Sponsor
- Candel Therapeutics, Inc.
Rectal Adenocarcinoma
Role of Neoadjuvent Radiotherapy in Locally Advanced Cancer Rectum
This is a retrospective study comparing neoadjuvent short course radiotherapy to conventional chemoradiation in locally advanced cancer rectum and the effect of both regimens in overall survival and disease free survival
- Trial name
- NCT04814784
- Testing
- Neoadjuvent radiotherapy either short or long course chemoradiation in treatment of locally advanced cancer rectum
- Where
- Egypt
- Volunteers
- 48 people
- Sponsor
- Amany sayed Abass
Glioblastom WHO Grade 4, GBM
TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma
This study is assessing the safety and tolerability of 5-ALA- mediated Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound, in patients who have just been diagnosed with bihemispheric (in both sides of the brain)…
- Conditions
- Glioblastom WHO Grade 4, GBM, bGBM, Butterfly GBM
- Trial name
- CV01-104 (NCT07862647)
- Testing
- 5-ALA, Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Alpheus Medical, Inc.
Gastric Cancer
Adjuvant Treatment of Gastric Cancer With Chemotherapy and Chemoradiotherapy (TRACE)
Post-operative radio-chemotherapy decrease the recurrence risk of gastric cancer(N Engl J Med 2001). However the chemotherapy regimen (5 fluorouracil IV bolus) used was toxic and suboptimal.
- Trial name
- TRACE (NCT00512304)
- Testing
- association chemotherapy and radiochemotherapy
- Where
- France
- Volunteers
- 63 people
- Sponsor
- University Hospital, Rouen
Gastric Cancer, Stomach Cancer
Adjuvant Intraperitoneal Floxuridine Added to Chemoradiation for Fully Resected Advanced Stomach Cancer
This study is to evaluate the efficacy and safety of addition of intraperitoneal (ip) Floxuridine to adjuvant chemoradiation therapy for patients under-going potentially curative stomach resection.
- Trial name
- NCT00858338
- Testing
- Potentially curative surgery, Floxuridine (IP), Adjuvant Chemoradiation therapy
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- NYU Langone Health
PMMR/MSS Adenocarcinoma of the Colon or Rectum, Neoadjuvant Chemoradiotherapy
Study on the Applicability of CCR Criteria in Rectal Cancer
This study aims to explore how well the usual ways of checking if rectal cancer patients are free of disease signs after treatment work for a new treatment method.
- Conditions
- PMMR/MSS Adenocarcinoma of the Colon or Rectum, Neoadjuvant Chemoradiotherapy, Immunotherapy, Complete Response
- Trial name
- NCT06794099
- Where
- China
- Volunteers
- 177 people
- Sponsor
- Peking University Cancer Hospital & Institute
Glioblastoma Multiforme
Vitamin D for Treatment of Glioblastoma Multiforme
This is non-randomized phase 2 study to assess efficacy and toxicity of long term high dose vitamin D3 given concurrently with chemo-radiotherapy (CCRT) containing temozolomide followed by adjuvant chemotherapy (ACT) with…
- Trial name
- NCT01181193
- Testing
- Surgery, Radiotherapy to tumour bed and/or residual tumour, Temozolomide
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Soroka University Medical Center
Nasopharyngeal Carcinoma
Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy
Currently, concurrent chemoradiotherapy with/without sequential chemotherapy is the standard treatment modality for intermediate risk NPC (stage II and T3N0M0) according to the National Comprehensive Cancer Network guideline.
- Trial name
- NCT02289807
- Testing
- Cisplatin, IMRT
- Where
- China
- Sponsor
- Sun Yat-sen University
Esophageal Cancer
PD-1 Inhibitor INCMGA00012 as Consolidation Therapy After Definitive Concurrent Chemoradiotherapy
This study is a randomized, multi-center, open-label, phase II study of a PD-1 inhibitor (INCMGA00012) versus observation as consolidation therapy after definitive concurrent chemoradiotherapy in patients with locally advanced…
- Trial name
- RHAPSODY (NCT04494009)
- Testing
- INCMGA00012
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- Asan Medical Center
Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
The trial aimed to compare QL1706 combined with induction chemotherapy plus concurrent chemoradiotherapy (IC+CCRT) versus IC+CCRT alone in High-risk Locoregionally-Advanced Nasopharyngeal Carcinoma (LANPC).
- Trial name
- NCT06749899
- Testing
- QL1706, Gemcitabine, Cisplatin
- Where
- 19 sites in China
- Volunteers
- 580 people
- Sponsor
- Sun Yat-Sen University Cancer Center
NSCLC (Advanced Non-small Cell Lung Cancer)
Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer
This is a randomized, controlled, multicenter clinical study that enrolled patients with unresectable bulky stage III NSCLC, with PFS as the primary endpoint.
- Trial name
- NCT07560358
- Testing
- After chemoimmunotherapy induction, followed by concurrent/sequential chemoradiotherapy and subsequent immune consolidation and maintenance therapy., adebrelimab,Radiation Therapy,Radiotherapy
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Nasopharyngeal Carcinoma
The Value of Concurrent Chemoradiotherapy for Stage II Nasopharyngeal Carcinoma
The purpose of this study is to verify the role of adding cisplatin chemotherapy to the intensity-modulated radiotherapy (IMRT) for stage II nasopharyngeal carcinoma.
- Trial name
- NCT01187238
- Testing
- cisplatin
- Where
- 3 sites in China
- Volunteers
- 84 people
- Sponsor
- Chinese Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.